Tucotuzumab celmoleukin
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM) . Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer[1][2].
Product Specifications
CAS Number
[339986-90-2]
Product Name Alternative
EMD 273066; huKS-IL2
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Tucotuzumabcelmoleukin]
References & Citations
[1]Eyvazi S, et al. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug Targets. 2018;18 (9) :857-868.|[2]Wang Z, et al. High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity. Biomolecules. 2024 Nov 2;14 (11) :1399.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
In112e 7.6 x 2.6 cm
Pieris sp., butterfly, head and mouth parts with proboscis w.m.
Ask
View Details sc-273948 250 mg
2- (benzylamino) -5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4 (3H) -one
Ask
View Details RC226093L3V 200 µL
GUCY1A3 (GUCY1A1) (NM_001130683) Human Tagged ORF Clone Lentiviral Particle
Ask
View Details